Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-559-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
LLNA (OECD 429): sensitising
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 Jan 2014 - 24 Feb 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- (adopted 22 Jul 2010)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- (adopted 30 May 2008)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.2600 (Skin Sensitisation)
- Version / remarks:
- (adopted Mar 2003)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt fuer Gesundheit und Lebensmittelsicherheit, Erlangen, Germany
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- other: CBA/CaOlaHsD
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories GmbH, Venray, The Netherlands
- Age at study initiation: 9-10 weeks
- Housing: in groups of 5 in IVC cages, type II L, polysulphone cages on Altromin saw fibre bedding (lot no. 131113)
- Diet: Altromin 1324 maintenance diet for rats and mice (lot no. 0801), ad libitum
- Water: tap water, sulphur acidified to a pH value of approximately 2.8 (drinking water, municipal residue control, microbial control at regular intervals), ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3
- Humidity (%): 55±10
- Air changes (per hr): at least 10
- Photoperiod (hrs dark / hrs light): 12/12 - Vehicle:
- dimethyl sulphoxide
- Concentration:
- 17, 33 and 67% (w/v)
- No. of animals per dose:
- 3 in prescreen test (2 in test group and 1 treated with vehicle alone as negative control)
5/group in main study - Details on study design:
- RANGE FINDING TESTS:
- Compound solubility: DMSO was selected as vehicle due to the solubility properties of the test item. The maximum technically applicable concentration of the test item in DMSO was determined to be 67%.
- Irritation: No irritation was observed at the maximum technically feasible concentration of 67% test item in DMSO and after treatment with DMSO alone.
- Lymph node proliferation response: Not conducted in pre-screen test.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: 3H-Methyl Thymidine (3HTdR) incorporation method
- Criteria used to consider a positive response: A substance is regarded as a "sensitiser" in the LLNA if at least one concentration of the test item results in a 3-fold or greater increase in 3HTdR incorporation into lymph node cells of the test group animals, relative to that recorded for the lymph nodes of control group animals (i.e. Stimulation index equal or greater than 3.0).
TREATMENT PREPARATION AND ADMINISTRATION:
Each mouse was treated by topical application of 25 µL of the selected solution to the entire dorsal surface of each ear. Topical applications were performed once daily over three consecutive days.
Five days after the first topical application all mice were dosed with 20 µCi 3HTdR by intravenous injection (Tail vein) of 250 µL of 3HTdR, diluted to a working concentration of 80 µCi/mL.
Approximately 5 h after the injection of 3HTdR all mice were sacrificed. The draining auricular lymph nodes were excised, individually pooled for each animal (2 lymph node per animal) and collected in phosphated buffered saline (PBS). A single cell suspension of pooled lymph node cells was prepared by gentle mechanical disaggregation through polyamide gauze (200 mesh size). After washing the gauze with PBS the cell suspension was pelleted in a centrifuge. The supernatant was discarded and the pellets were resuspended with PBS: The washing procedure was repeated. After the final wash each pellet was resuspended in approximately 1 mL 5% trichloroacetic acid (TCA) at approximately 4°C for approximately 18 h for precipitation of macromolecules. Each precipitate was once washed again, resuspended in 1 mL 5% TCA and 7 mL scintillation fluid was added. Then this solution was transferred into scintillation vials and stored at room temperature overnight.
3HTdR incorporation was measured in a ß-counter and expressed as the number of disintegrations per minute (DPM). Similarly, background 3HTdR levels were also measured (5% TCA). Determination of radioactivity was performed individually for each animal. - Positive control substance(s):
- other: p-phenylenediamine (CAS 106-50-3, Sigma, purity >98%, lot no. SLBC7171V), 1% in DMSO
- Positive control results:
- The recent reliability check was performed in Nov 2013. The DPM/node were 1891.9±387.6 for the negative control animals and 18051.7±1056.2 for the positive control animals. SI of the positive control animals was 9.5±0.6. The sensitivity of the test system was thus confirmed.
- Key result
- Parameter:
- SI
- Value:
- 5
- Variability:
- ± 1.4
- Test group / Remarks:
- 17% solution
- Key result
- Parameter:
- SI
- Value:
- 6
- Variability:
- ± 0.6
- Test group / Remarks:
- 33% solution
- Key result
- Parameter:
- SI
- Value:
- 8.9
- Variability:
- ± 3.2
- Test group / Remarks:
- 67% solution
- Key result
- Parameter:
- EC3
- Value:
- 4.51
- Parameter:
- other: disintegrations per minute (DPM)/node
- Value:
- 1 539.4
- Variability:
- ± 353.1
- Test group / Remarks:
- negative control
- Parameter:
- other: disintegrations per minute (DPM)/node
- Value:
- 7 706.9
- Variability:
- ± 2165.6
- Test group / Remarks:
- 17% solution
- Parameter:
- other: disintegrations per minute (DPM)/node
- Value:
- 9 204.6
- Variability:
- ± 898.8
- Test group / Remarks:
- 33% solution
- Parameter:
- other: disintegrations per minute (DPM)/node
- Value:
- 13 683.1
- Variability:
- ± 9886.7
- Test group / Remarks:
- 67% solution
- Interpretation of results:
- Category 1B (indication of skin sensitising potential) based on GHS criteria
- Conclusions:
- CLP: Cat 1B, H317
Reference
Pre-screen test
Neither signs of systemic toxicity nor signs of irritation at any application site could be detected in any animal. One animal showed weight loss of 4 g. All other animals showed the expected weight development, which includes a weight loss of up to 2 g throughout the duration of the pre-screen test.
Main study
All animals survived throughot the study period. On Day 6, one animal of the 33% group showed bodyweight loss, hypothermia, dehydration, piloerection and lymph nodes with a small size. All other test group animals showed enlarged lymph nodes, and their body weights developed as expected. Eschar was observed in all animals of the test groups on Day 6. As only one animal of the mid dose group (33%) showed clinical signs, a clear test item relation cannot be concluded.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
Skin sensitisation of Reaction mass of ammonium diaqua[bis(oxalate)]oxoniobate(1-) hydrate and ammonium hydrogen oxalate oxalic acid (1:1:1) dihydrate was investigated by means of Local Lymph Node Assay (LLNA). In the available key study (CBMM Europe BV, Key, 2014, LLNA) the ears of 5 mice per group were topically treated with concentrations of 17, 33 and 67% of the test item in DMSO for 3 consecutive days. Five days after the first treatment the mice received an intravenous injection of 3H-Methyl Thymidine (3HTdR). Five hours after treatment the mice were euthanised, the cells of the draining auricular lymph nodes were dissected, and the incorporated radioactivity was determined as number of disintegrations per minute (DPM) by means of a β-scintillation counter. Stimulation Indices were calculated as ratio of respective DPM of the individual animals from the treated groups versus the mean DPM of the control group. Subsequently, group mean Stimulation Indices of 5.0±1.4, 6.0±0.6 and 8.9±3.2 were determined for the 17, 33 and 67% group, respectively. According to the criteria of OECD Guideline 429 the test item has to be regarded as a skin sensitiser.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
A study assessing the potential risk of respiratory sensitisation is not required according to Annex VII-X of Regulation (EC) No 1907/2006.
Justification for classification or non-classification
The available data are reliable and suitable for classification. Based on these data, Reaction mass of ammonium diaqua[bis(oxalate)]oxoniobate(1-) hydrate and ammonium hydrogen oxalate oxalic acid (1:1:1) dihydrate meets the criteria to be classified for skin sensitisation (Cat 1B, H317) according to EC/1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.